louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02344862: Study of FYU-981 in Hyperuricemia With or Without Gout
Official title: Exploratory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIa) Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Hyperuricemia
Lead sponsor: Fuji Yakuhin Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2015-01-26
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is exploratory investigation of safety and efficacy (dose response and optimal dose according to the percent reduction from baseline in serum urate level at the final visit) of FYU-981 administered orally to hyperuricemic patients with and without gout for 8 weeks (dose-escalating initial period: 4 weeks followed by maintenance period: 4 weeks) by the method of randomized (dynamic allocation), placebo-controlled, double-blind, parallel group comparison.


Eligibility criteria: Inclusion Criteria:

* Hyperuricemic or gout patients
* Serum urate level:

\>= 7.0mg/dL in patients with history of gout, or \>= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or \>= 9.0mg/dL

Exclusion Criteria:

* Gouty arthritis within two weeks before start of study treatment
* Secondary hyperuricemia
* HbA1c: \>= 8.4%
* Uric acid-overproduction type in the classification of hyperuricemia
* History of, clinically significant cardiac, hematologic and hepatic disease
* Kidney calculi or clinically significant urinary calculi
* eGFR: \< 60mL/min/1.73m\^2
* Systolic blood pressure: \>= 180 mmHg
* Diastolic blood pressure: \>= 110 mmHg

Primary outcomes:
measure: Percent reduction from baseline in serum urate level at the final visit
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Tokyo
country: Japan
facility: Japan
Study officials:
References:
citation: Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study. Clin Exp Nephrol. 2020 Mar;24(Suppl 1):44-52. doi: 10.1007/s10157-019-01802-w. Epub 2019 Nov 21.
Clinical trial NCT01606462: Oxytocin and Social Cognition
Official title: Double-blind, Placebo-controlled, Randomized Study: Oxytocin and OXTR-genotypes Influence Behavioral and Neural Social Reactions
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Male Volunteers
Keywords: oxytocin
social cognition
fMRI
oxytocin receptor gene
Lead sponsor: University Hospital, Bonn
Sponsor class: OTHER
First posted: 2012-05-25
Enrollment: 153
Sex: MALE
Minimum age (years): 20
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to determine whether oxytocin influences memory of social stimuli and reaction to social stimuli. Furthermore the investigators explore the effect of oxytocin receptor (OXTR) polymorphism in terms of behavioral and neural responses to social stimuli.

Detailed description: The prevailing view of OXT as a key facilitator of prosocial behaviors has been highly influenced by a plethora of studies in healthy volunteers, which demonstrated increased interpersonal trust, generosity, social learning/empathy and positively biased social stimulus processing as a result of OXT treatment. However, this interpretation is challenged by observations that OXT also promotes envy and schadenfreude (gloating), ethno-centrism (including prejudice, xenophobia, and racial bias), and defensive aggression towards outsiders.We investigate the neural correlates of emotion perception and subsequent memory effects of aversive and neutral stimuli. Tthe oxytocin effect on personal space is questioned. Additionally the effect of OXTR polymorphism regarding behavioral and neural response is explored.

Eligibility criteria: Inclusion Criteria:

* Healthy male volunteers

Exclusion Criteria:

* Current or past psychiatric disease
* Current or past physical illness
* Psychoactive medication
* Tobacco smokers
* MRI contraindication

Primary outcomes:
measure: neural correlates of emotion perception and subsequent memory effects of aversive and neutral stimuli
timeFrame: two years
Secondary outcomes:
measure: the effect of oxytocin receptor (OXTR) polymorphism in terms of behavioral and neural responses to social stimuli
timeFrame: two years
measure: The oxytocin effect on social behavior e.g. personal space is questioned
timeFrame: two years
Other outcomes:
Locations:
city: Bonn
country: Germany
facility: Department of Psychiatry, University of Bonn
Study officials:
affiliation: Department of Psychiatry, University of Bonn, Germany
name: Rene Hurlemann, MSc MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01913262: IFH Depression Registry 2013
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Depression
Keywords: depression
phq9
phq-9
standard treatment
Lead sponsor: The Institute for Family Health
Sponsor class: OTHER
First posted: 2013-08-01
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Community health patients in behavioral health treatment

Brief summary: This is an observational registry intended to track depression scores of patients over time in treatment.


Eligibility criteria: Inclusion Criteria:

* Patients with PHQ-9 score greater than or equal to 10, have a depression diagnosis active on the problem list, or have had a depression encounter diagnosis used in the past year, and are in behavioral health treatment at the Institute.

Exclusion Criteria:

* Patients under the age of 18

Primary outcomes:
measure: Depression scores on PHQ-9 depression screening
timeFrame: 16 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: The Institute for Family Health
state: New York
Study officials:
References:
Clinical trial NCT04809662: Comparing Immune Responses to Topical Imiquimod
Official title: Comparing Immune Responses to Topical Imiquimod
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Actinic Keratoses
Keywords: imiquimod
aldara
Lead sponsor: University of California, Davis
Sponsor class: OTHER
First posted: 2021-03-22
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who will use topical imiquimod as standard of care and who are without immune-mediated systemic disease

Brief summary: The study is a basic science research study that is designed to characterize and compare the immune response in individuals who are designated as ABO blood group secretors, meaning they have a functional copy of the FUT2 gene versus those patients who are designated ABO non-secretors after application of topical imiquimod to these patients.


Eligibility criteria: Inclusion Criteria:

* Individuals between 18 to 85 years of age
* Patients with a diagnosis that will result in treatment with imiquimod as standard of care, specifically actinic keratosis

Exclusion Criteria:

* Younger than 18 years or older than 85 years.
* History of hypersensitivity/ allergic reaction or adverse reaction to imiquimod
* Individuals with a diagnostic biopsy and supportive histology of a cutaneous immune-mediated disease (e.g. psoriasis and mycosis fungoides, etc.) or diseases of the hematopoietic system, liver and the gastrointestinal tract (e.g. aplastic anemia, Crohn's disease, Ulcerative Colitis, Primary Sclerosing Cholangitis (PSC), Primary Biliary Cirrhosis, acute and chronic graft versus host disease (GVHD)).
* Individuals with autoantibodies plus objective evidence of end organ damage related to a cutaneous immune-mediated disease (e.g. psoriasis and mycosis fungoides, etc.) or diseases of the hematopoietic system, liver and the gastrointestinal tract (e.g. aplastic anemia, Crohn's disease, Ulcerative Colitis, Primary Sclerosing Cholangitis (PSC), Primary Biliary Cirrhosis, acute and chronic graft versus host disease (GVHD)).
* Individuals with a history of serious infection within the last 6 months.
* Individuals with tuberculosis, HIV, or hepatitis B, or C.
* Patients unable to provide consent
* Incarcerated individuals

Primary outcomes:
measure: Immune response
timeFrame: 5 years
Secondary outcomes:
measure: Monitoring
timeFrame: 1 year
measure: Flow cytometry
timeFrame: 3 years
measure: Immunohistochemistry
timeFrame: 3 years
Other outcomes:
Locations:
city: Sacramento
country: United States
facility: University of California Davis
state: California
Study officials:
References:
Clinical trial NCT04346862: Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease
Official title: Phase IV Study to Evaluate the Effect of Improvement in Cognitive Impairment of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Mild Cognitive Impairment
Lead sponsor: Hanmi Pharmaceutical Company Limited
Sponsor class: INDUSTRY
First posted: 2020-04-15
Enrollment: 636
Sex: ALL
Minimum age (years): 55
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of Acetyl-L-carnitine in patient with Mild Cognitive Impairment associated with chronic cerebrovascular disease.


Eligibility criteria: Inclusion Criteria:

* Age between 55 and 85 years old
* Patients with chronic cerebrovascular disease, who have modified Fazekas scale grade 2 \~ 3
* Patients wtih a diagnosis of MCI
* MOCA-K of 23 or less
* Patients who provided a signed written informed consent form

Exclusion Criteria:

* Patiens who are uneducated or illiterate
* Patiens previously treated with dementia
* Patients who received a nootropic agent or thyroid hormone within 4 weeks of visit 1
* Patients with cognitive impairment due to diseases other than cerebrovascular disease
* Patients with severe depression, schizophrenia, alcoholism, and drug dependence

Primary outcomes:
measure: Interference score using K-CWST(Korean-Color Word Stroop Test)
timeFrame: 24 week
measure: Montreal Cognitive Assessment Korean(MOCA-K)
timeFrame: 24 week
Secondary outcomes:
measure: Korean Trail Making Test Elderly(K-TMT-e)
timeFrame: 24 week
measure: EQ-5D
timeFrame: 24 week
measure: Clinical Global Impression -Improvement (CGI-I)
timeFrame: 24 week
Other outcomes:
Locations:
city: Incheon
country: Korea, Republic of
facility: Catholic Kwandong University International St. Mary'S Hospital
Study officials:
References:
Clinical trial NCT06945562: Influence of Collagen Cone on Jumping Gap Management Around Dental Implants
Official title: Influence of Collagen Cone on Jumping Gap Management Around Dental Implants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tooth Loss
Keywords: immediate implant
collagen cone
esthatic zone
jumping gap
Lead sponsor: Faculty of Dental Medicine for Girls
Sponsor class: OTHER_GOV
First posted: 2025-04-25
Enrollment: 16
Sex: ALL
Minimum age (years): 30
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The present study will be performed to assess the clinical and radiographic effect of collagen cone for bone growth in immediate implants.

Detailed description: Improve width and length of buccal plate of alveolar bone, bone density around dental implamts in esthetics zone.

Eligibility criteria: Inclusion Criteria:

* Patients aged between 30-50 years.
* Good general health.
* Adequate bone volume at the implant site.
* Non-compromised periodontal status.

Exclusion Criteria:

* Presence of parafunctional habits (e.g., bruxism, clenching, excessive gum chewing, lip or fingernail biting).
* Smokers.
* Patients receiving chemotherapy or radiotherapy.
* Alcohol or drug abuse.
* Pregnancy and lactation.
* Use of drugs that may affect bone metabolism.

Primary outcomes:
measure: Clinical Bleeding Index
timeFrame: from 0 to 9 month
measure: Vertical Bone Loss
timeFrame: from 0 to 9 month
measure: Buccal Plate Width
timeFrame: From 0 to 9 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Hala Fathy Abd El-Fattah Azzam
Study officials:
affiliation: Al-Azhar University
name: Abeer Gawish, professor
role: STUDY_DIRECTOR
affiliation: Al-Azhar University
name: lobna Abd-El Aziz, Lecturer
role: STUDY_DIRECTOR
References:
Clinical trial NCT02468362: Long Term Outcomes After Laparoscopic Intersphincteric Resection With Total Mesorectal Excision for Low Rectal Cancer.
Official title: Long Term Outcomes After Laparoscopic Intersphincteric Resection With Total Mesorectal Excision for Low Rectal Cancer: a Double Blind Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Low Rectal Cancer
Keywords: Intersphincteric resection
laparoscopic rectal rescetion
total mesorectal excsison
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2015-06-10
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Through a double blinded study, patients with low rectal cancer will be randomized into two equal groups to compare between the 5 year disease free survival as a primary outcome measure.


Eligibility criteria: Inclusion Criteria:

* Low rectal cancer below 5 cm from the anal verge
* Fit for laparoscopic total mesorectal excsion
* T2, T3 rectal cancer
* No distant metstasis

Exclusion Criteria:

* T1, AND T4
* Distant metastasis
* Tumor infiltrating the dentate line
* unwilling to participate

Primary outcomes:
measure: Disease Free survival
timeFrame: 5 years
Secondary outcomes:
measure: Local recurrence
timeFrame: 5 years
measure: Distant metstasis
timeFrame: 5 years
measure: 5 year survival
timeFrame: 5 years
Other outcomes:
Locations:
Study officials:
affiliation: Oncology centre of mansoura university
name: Osama Eldamshety, PhD, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Oncology centre of mansoura university
name: Sherif Kotb, PhD, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Oncology centre of mansoura university
name: Nazem Shams, PhD, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Oncology centre of mansoura university
name: Ashraf Khater, Phd, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04166162: Businesses That Care - Zacatecas
Official title: Businesses That Care - Zacatecas
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alcohol Drinking
Keywords: Underage Drinking
Lead sponsor: University of Miami
Sponsor class: OTHER
Collaborators: name: AB InBev Foundation
First posted: 2019-11-18
Enrollment: 555
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to develop and implement a community-based prevention initiative to prevent youth alcohol use and abuse in Zacatecas, Mexico.


Eligibility criteria: Inclusion Criteria for Parent Participants:

* Must be 18 years or older who are actively working at one of the four BTC participating companies in Zacatecas, Mexico.
* Must be residents of the Cities of Zacatecas or Guadalupe, in the state of Zacatecas, Mexico.
* Workers who are illiterate or otherwise literary challenged are included.
* Must have at least one child (biological, step or adopted) between the ages of 8 and 16 years of age.

Exclusion Criteria for Parent Participants:

* Doesn't speak Spanish.

Inclusion Criteria for Children Participants:

* Must be a child (biological, step or adopted) of a BTC employee who participated in the study.
* Must be between the age of 11 to 16 years.

Exclusion Criteria for Children Participants:

* Doesn't speak Spanish.

Primary outcomes:
measure: Sustainability of BTC coalition
timeFrame: 1 year
measure: Change in risk behaviors in TBD Intervention Recipients
timeFrame: Baseline, 6 weeks
measure: Change in risk behaviors in SDS Intervention Recipients
timeFrame: Pre-SDS Intervention, Post-SDS Intervention (2 hours)
measure: Change in risk behaviors in BIMI Intervention Recipients
timeFrame: Baseline, 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Zacatecas
country: Mexico
facility: Business That Care Participating Companies
Study officials:
affiliation: University of Miami
name: Eric Brown
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01120262: S9346A Blood Samples From Patients With Metastatic Prostate Cancer Previously Treated With Bicalutamide and Goserelin
Official title: Germline Polymorphisms Associated With the PSA Response in Men With Metastatic Prostate Cancer Treated With Androgen Deprivation Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prostate Cancer
Keywords: recurrent prostate cancer
stage IV prostate cancer
Lead sponsor: SWOG Cancer Research Network
Sponsor class: NETWORK
Collaborators: name: National Cancer Institute (NCI)
First posted: 2010-05-10
Enrollment: 545
Sex: MALE
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: S9346 patients

Brief summary: RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is studying blood samples from patients with metastatic prostate cancer previously treated with bicalutamide and goserelin.

Detailed description: OBJECTIVES:

* To test the association between serum PSA response (\< 4 ng/mL) at 7 months with inherited variability of germline single nucleotide polymorphisms, in a set of candidate genes, in patients with metastatic prostate cancer treated with combination induction androgen-deprivation therapy comprising bicalutamide and goserelin.

OUTLINE: DNA extracted from whole blood or serum samples is analyzed for inherited variability of germline single nucleotide polymorphisms.

Eligibility criteria: DISEASE CHARACTERISTICS:

* Diagnosed with metastatic prostate cancer
* Accrued to SWOG-9346 and received androgen-deprivation therapy (ADT)
* Must have serum PSA values from the beginning to the end of 8 courses of ADT
* Must have whole blood or serum samples available

PATIENT CHARACTERISTICS:

* Caucasian and African-American participants

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics

Primary outcomes:
measure: Serum PSA values at 7 months
timeFrame: 7 months
measure: Role of genetic variation in response to therapy
timeFrame: baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Michigan Rogel Cancer Center
name: Kathleen A. Cooney, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05958862: Stability of Driving Pressure Changes During "Best Positive End Expiratory Pressure (PEEP)" Trial
Official title: Stability of Driving Pressure Changes During "Best Positive End Expiratory Pressure (PEEP)" Trial
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Acute Respiratory Failure
Acute Respiratory Distress Syndrome
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2023-07-25
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult medical intensive care patients undergoing invasive mechanical ventilation who meet above inclusion/exclusion criteria

Brief summary: The goal of this study is to better understand in changes in lung compliance as indicated by driving pressure (a non-invasive marker) following changes in positive end expiratory pressure (PEEP; a standard of care ventilator parameter).

The main question it aims to answer is: The time to stability of driving pressure after a change in PEEP is made Type of study: observational study participant population/health conditions

Participants will undergo a "best PEEP trial" which is a standard intensive care intervention for patients undergoing invasive mechanical ventilation. This involves changing the patient's PEEP and looking for response in driving pressure. This will be done in a more protocolized format and data will be collected.


Eligibility criteria: Inclusion Criteria:

* Adult patients \>18 years of age
* Undergoing intubation and mechanical ventilation in Medical Intensive Care Unit (MICU) or Medical Critical Care Unit (MCCU) at the University of Alabama Birmingham.

Exclusion Criteria:

* Prisoner
* Pregnant
* Age \<18 years of age
* Intensive Care Unit (ICU) team declines participation
* Unstable oxygenation (requiring 100% FiO2 to maintain saturations greater than 90% oxygen saturation following initial PEEP titration by primary team)
* Hemodynamic instability: vasopressor requirement of \>0.3 mcg/kg/min of norepinephrine or equivalent
* Pneumomediastinum
* Pneumothorax without chest tube
* Previous enrolled in trial
* Need for immediate travel out of ICU following intubation for procedures, tests

Primary outcomes:
measure: Stability of change in Driving Pressure after PEEP manipulation
timeFrame: 10 minutes total
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: University of Alabama at Birmingham
name: Ryan L Goetz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01402362: Prevalence of Glucose Intolerance and Risk Factors in Ethiopian Immigrants in Israel; Follow-up Study.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Diabetes Mellitus
Glucose Intolerance
Keywords: Ethiopians
Diabetes Mellitus
Glucose tolerance
Israel
Included in the year 2000 study
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2011-07-26
Enrollment: 550
Sex: ALL
Minimum age (years): 25
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Ethiopian immigrants to Israel living in Hadera.

Brief summary: High risk population: Screening for impaired glucose tolerance.


Eligibility criteria: Inclusion Criteria:

* Participation in the year 2000 study
* Signature of Informed Consent Form

Exclusion Criteria:

Pregnancy

-

Primary outcomes:
measure: Percent of patients with Diabetes Mellitus or impaired glucose tolerance
timeFrame: Day 1 of study
Secondary outcomes:
measure: Prevalence of hypertension and hyperlipidemia
timeFrame: Day 1 of study
Other outcomes:
Locations:
city: Hadera
country: Israel
facility: Diabetes and Endocrinology Unit, Hillel Yaffe MC, POB169
Study officials:
References: